Evolution of the cohort study

Epidemiologic Reviews

Volumn 20, Issue 1, 1998, Pages 1-14

  Samet, Jonathan M ^a   Muñoz, Alvaro ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CIGARETTE SMOKING; COHORT ANALYSIS; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG CARCINOMA; NOMENCLATURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0031706457     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a017964     Document Type: Review

References (108)

1. Armenian HK (ed). Applications of the case-control method. Epidemiol Rev 1994;16:1-164.
2. Breslow NE, Day NE. Statistical methods in cancer research. Vol II - The design and analysis of cohort studies. Lyon, France: International Agency for Research on Cancer, 1987. (IARC scientific publications no. 82).
3. Cox DR, Oakes D. Analysis of survival data. New York, NY: Chapman and Hall, 1984.
4. Dwyer JH, Feinleib M, Lippert P, et al. Statistical models for longitudinal studies of health. New York, NY: Oxford University Press, 1992.
5. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. New York, NY: Oxford University Press, 1994.
6. Liddell FDK. The development of cohort studies in epidemiology: a review. J Clin Epidemiol 1988;41:1217-37.
7. Changes in cigarette-related disease risks and their implication for prevention and control. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, 1997. (NIH publication no. 97-4213).
8. Bailar JC III, Mosteller F. Medical uses of statistics. 2nd ed. Waltham, MA: NEJM Books, 1992.
9. MacMahon B, Trichopoulos D. Epidemiology: principles and methods. 2nd ed. Boston, MA: Little, Brown, 1996.
10. Last JM. A dictionary of epidemiology. 3rd ed. New York, NY: Oxford University Press, 1995.
11. Eyler JM. The conceptual origins of William Farr's epidemiology: numerical methods and social thought in the 1830s. In: Lilienfeld AM, ed. Times, places, and persons: aspects of the history of epidemiology. Baltimore, MD: Johns Hopkins University Press, 1980:1-21.
12. Lew EA. Actuarial contributions to life table analysis. Natl Cancer Inst Monogr 1985;67:29-36.
13. Bernstein PL. Against the gods: the remarkable story of risk. New York, NY: Wiley, 1996.
14. Singer RB. Examples of early mortality follow-up studies. Natl Cancer Inst Monogr 1985;67:15-21.
15. Specialized mortality investigation. New York, NY: Actuarial Society of America, 1903.
16. Sartwell PE. Editorial: The time factor in studies of the outcome of chronic disease. Am Rev Tuberc 1951;63: 608-12.
17. Comstock GW. Early studies of tuberculosis. Natl Cancer Inst Monogr 1985;67:23-7.
18. Brown L, Pope EG. The post-discharge mortality among the patients of the Adirondack Cottage Sanitarium. Am Med 1904;8:879-82.
19. Elderton WP, Perry SJ. Drapers' company (London, England). Research memoirs. Studies in national deterioration VI. A third study of the statistics of pulmonary tuberculosis: the mortality of the tuberculous and sanatorium treatment. London, England: Dalau, 1910.
20. Frost WH. The age selection of mortality from tuberculosis in successive decades. Am J Hyg 1939;30A:91-6.
21. Andvord KF. What can we learn by studying tuberculosis generations? (English translation by Gerard Wijsmuller). Norsk mag Lægevidensk 1930;91:642-60.
22. Frost WH. Risk of persons in familial contact with pulmonary tuberculosis. Am J Public Health 1933;23:426-32.
23. Zeidberg LD, Gass RS, Dillon A, et al. The Williamson County Tuberculosis Study: a twenty-four-year epidemiologic study. Am Rev Respir Dis 1963;87(no.3, part 2):1-88.
24. Dawber TR. The Framingham study: the epidemiology of atherosclerotic disease. Cambridge, MA: Harvard University Press, 1980.
25. Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis 1967;20:511-24.
26. Schull WJ. Effects of atomic radiation: a half-century of studies from Hiroshima and Nagasaki. New York, NY: Wiley-Liss, 1995.
27. Samet JM. Epidemiologic studies of ionizing radiation and cancer: past successes and future challenges. Environ Health Perspect 1997;105(Suppl 4):883-9.
28. Lundin FE, Wagoner JK, Archer VE. Radon daughter exposure and respiratory cancer, quantitative and temporal aspects. National Instutute for Occupational Safety and Health-National Institute of Environmental Health Sciences joint monograph no. 1. Washington, DC: US Department of Health, Education, and Welfare, Public Health Service, 1971.
29. National Research Council Committee on Health Risks of Exposure to Radon. Report of the committee on health risks of exposure to radon (BEIR VI). Washington, DC: National Academy Press, 1997.
30. Whittemore AS, McMillan A. Analyzing cohort data: application to US uranium miners. In: Prentice RL, Whittemore AS, eds. Environmental epidemiology: risk assessment. Philadelphia, PA: SIAM, 1982:65-81.
31. Lubin JH, Gail MH. On power and sample size for studying features of the relative odds of disease. Am J Epidemiol 1990;131:552-66.
32. Thomas DC, McNeill KG, Dougherty C. Estimates of lifetime lung cancer risks resulting from Rn progeny exposure. Health Phys 1985;49:825-46.
33. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits: a preliminary report. Br Med J 1954;1: 1451-5.
34. Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994;309:901-11.
35. Hammond EC, Horn D. Smoking and death rates report on forty-four months of follow-up of 187,783 men. I. Total mortality. II. Death rates by cause. JAMA 1958;166: 1159-72, 1294-308.
36. Dorn HF. Tobacco consumption and mortality from cancer and other diseases. Public Health Rep 1959;74:981-93.
37. US Department of Health Education and Welfare, Public Health Service. Smoking and health; report of the advisory committee to the Surgeon General of the Public Health Service. Washington, DC: US GPO, 1964.
38. Case RAM, Hosker ME, McDonald DB, et al. Tumors of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Part I: The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Br J Ind Med 1954; 11:75-104.
39. Doll R. Mortality from lung cancer in asbestos workers. Br J Ind Med 1955;12:81-6.
40. Selikoff IJ, Hammond EC, Seidman H. Mortality experience of insulation workers in the United States and Canada, 1943-1976. Ann NY Acad Sci 1979;330:91-116.
41. Hammond EC. Smoking in relation to the death rates of one million men and women. Natl Cancer Inst Monogr 1966;19: 127-204.
42. Fletcher CM, Peto R, Tinker C, et al. The natural history of chronic bronchitis and emphysema: an eight year study of early chronic obstructive lung disease in working men in London. New York, NY: Oxford University Press, 1976.
43. Higgins MW, Keller JB. Predictors of mortality in the adult population of Tecumseh. Arch Environ Health 1970;21: 418-24.
44. Heyden S, Cassel JC, Bartel A, et al. Body weight and cigarette smoking as risk factors. Arch Intern Med 1971;128: 915-19.
45. Berkman LF, Syme SL. Social networks, host resistance, and mortality: a nine-year follow-up study of Alameda County residents. Am J Epidemiol 1979;109:186-204.
46. Menkes MS, Comstock GW, Vuilleumier JP, et al. Serum beta-carotene, vitamins A and E, selenium, and the risk of lung cancer. N Engl J Med 1986;315:1250-4.
47. Lebowitz MD, Burrows B. Tucson epidemiologic study of obstructive lung diseases. II. Effects of in-migration factors on the prevalence of obstructive lung diseases. Am J Epidemiol 1975;102:153-63.
48. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989;129:687-702.
49. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1: 263-76.
50. Lee ET, Welty TK, Fabsitz R, et al. The Strong Heart Study: a study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol 1990;132:1141-55.
51. Newcombe HB. Handbook of record linkage: methods for health and statistical studies, administration and business. New York, NY: Oxford University Press, 1988.
52. Cox CS, Rothwell ST, Madans JH, et al. Plan and operation of the NHANES I Epidemiologic Followup Study, 1987. National Center for Health Statistics. Vital Health Stat [1] 1992;(27):1-190.
53. Colditz GA, Willett WC, Hunter DJ, et al. Family history, age, and risk of breast cancer: prospective data from the Nurses' Health Study. JAMA 1993;270:338-43.
54. Polk BF, Fox R, Brookmeyer R, et al. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N Engl J Med 1987; 316:61-6.
55. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
56. Mantel N. Synthetic retrospective studies and related topics. Biometrics 1973;29:479-86.
57. Liddell FDK, McDonald JC, Thomas DC. Methods of cohort analysis: appraisal by application to asbestos mining. J R Stat Soc 1977;140:469-91.
58. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73: 1-11.
59. Greenland S. Response and follow-up bias in cohort studies. Am J Epidemiol 1977;106:184-7.
60. Royall RM. Statistical evidence: a likelihood paradigm. New York, NY: Chapman and Hall, 1997.
61. Lehmann EL. Theory of point estimation. New York, NY: Springer-Verlag, 1997.
62. Tufte ER. The visual display of quantitative information. Cheshire, CT: Graphics Press, 1983.
63. Gange SJ, Muñoz A, Chmiel JS, et al. Identification of inflections in T-cell counts among HIV-1 infected individuals and relationship with progression of clinical AIDS. Proc Natl Acad Sci 1998 (in press).
64. Cox DR. Regression models and life tables. J R Stat Soc 1972;B34:187-202.
65. Jennrich RI, Schluchter MD. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986;42:805-20.
66. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
67. Korn EL, Whittemore AS. Methods for analyzing panel studies of acute health effects of air pollution. Biometrics 1979;35:795-802.
68. Whittemore AS, Korn EL. Asthma and air pollution in the Los Angeles area. Am J Public Health 1980;70:687-96.
69. Rosner B, Muñoz A. Conditional linear models for longitudinal data. In: Dwyer JH, Feinleib M, Lippert P, et al., eds. Statistical models for longitudinal studies of health. New York, NY: Oxford University Press, 1992:115-37.
70. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
71. Kupper LL, Haseman JK. The use of a correlated binomial model for the analysis of certain toxicological experiments. Biometrics 1978;34:69-76.
72. Breslow N. Extra-Poisson variation in log-linear models. Appl Stat 1984;33:38-44.
73. Segal MR. Regression trees for censored data. Biometrics 1988;44:35-48.
74. Ciampi A, Lawless JF, McKinney SM, et al. Regression and recursive partition strategies in the analysis of medical survival data. J Clin Epidemiol 1988;41:737-48.
75. McCullagh P, Nelder JA. Generalized linear models. New York, NY: Chapman and Hall, 1989.
76. Hastie TJ, Tibshirani RJ. Generalized additive models. New York, NY: Chapman and Hall, 1990.
77. Muñoz A, Sabin CA, Phillips AN. The incubation period of AIDS. AIDS 1997;11(Suppl A):S69-76.
78. Muñoz A, Xu J. Models for the incubation of AIDS and variations according to age and period. Stat Med 1996;15: 2459-73.
79. Detels R, Muñoz A, McFarlane G. Effectiveness of highly active antiretroviral therapy on the natural history of HIV/ AIDS in a large cohort of seroconverters. JAMA 1998 (in press).
80. Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med 1992;11:1871-9.
81. Muñoz A, Sunyer J. Comparison of semiparametric and parametric survival models for the analysis of bronchial responsiveness. Am J Respir Crit Care Med 1996; 154(Suppl):S234-9.
82. Wacholder S, Gail MH, Pee D, et al. Alternative variance and efficiency calculations for the case-cohort design. Biometrika 1989;76:117-23.
83. Muñoz A, Gange SJ. Methodological issues for biomarkers and intermediate outcomes in cohort studies. Epidemiol Rev 1998;20:15-28.
84. Lamarca R, Alonso J, Gomez G, et al. Left-truncated data with age as time scale: an alternative for survival in the elderly. J Gerontol A Biol Sci Med Sci (in press).
85. Armstrong BK, White E, Saracci R. Principles of exposure measurement in epidemiology. New York, NY: Oxford University Press, 1992.
86. Carroll RJ, Ruppert D, Stefanski LA. Measurement error in nonlinear models. London, England: Chapman and Hall, 1995.
87. Tsiatis AA, De Gruttola V, Wulfsohn MS. Modeling the relationship of survival to longitudinal data measured with error: applications to survival and CD4 counts in patients with AIDS. J Am Stat Assoc 1995;90:27-37.
88. De Gruttola V, Tu XM. Modelling progression of CD4-lymphocyte count and its relationship to survival time. Biometrics 1994;50:1003-14.
89. Diggle P, Kenward MG. Informative drop-out in longitudinal data analysis. Appl Stat 1994;43:49-93.
90. Little RJA. Modeling the drop-out mechanism in repeated-measures studies. J Am Stat Assoc 1995;90:1112-21.
91. Hogan JW, Laird NM. Mixture models for the joint distribution of repeated measures and event times. Stat Med 1997;16:239-57.
92. Hogan JW, Laird NM. Model-based approaches to analysing incomplete longitudinal and failure time data. Stat Med 1997;16:259-72.
93. Chmiel JS, Detels R, Kaslow RA, et al. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am J Epidemiol 1987;126:568-77.
94. Kingsley LA, Zhou SY, Bacellar H, et al. Temporal trends in human immunodeficiency virus type 1 seroconversion 1984-1989: a report from the Multicenter AIDS Cohort Study (MACS). Am J Epidemiol 1991;134:331-9.
95. Margolick JB, Muñoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection: the Multicenter AIDS Cohort Study. Nat Med 1995;1:674-80.
96. Centers for Disease Control and Prevention. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47(RR-5): 1-82.
97. Muñoz A, Wang MC, Bass S, et al. Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men: Multicenter AIDS Cohort Study Group. Am J Epidemiol 1989;130:530-9.
98. Muñoz A, Carey V, Taylor JM, et al. Estimation of time since exposure for a prevalent cohort. Stat Med 1992;11: 939-52.
99. Taylor JM, Muñoz A, Bass SM, et al. Estimating the distribution of times from HIV seroconversion to AIDS using multiple imputation: Multicenter AIDS Cohort Study. Stat Med 1990;9:505-14.
100. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
101. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA 1996; 275:1329-34.
102. Jacobson LP, Kirby AJ, Polk S, et al. Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984-1991. Am J Epidemiol 1993;138:952-64.
103. Muñoz A, Schrager LK, Bacellar H, et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. Am J Epidemiol 1993;137:423-38.
104. Phair J, Jacobson L, Detels R, et al. Acquired immune deficiency syndrome occurring within 5 years of infection with human immunodeficiency virus type-1: the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1992;5: 490-6.
105. Gange SJ, Jacobson LP, Muñoz A. Parametric models to assess tracking of categorical high-risk sexual behaviour for HIV infection. Stat Med 1996;15:2323-36.
106. Muñoz A, Hoover DR. Use of cohort studies for evaluating AIDS therapies. New York, NY: Wiley, 1995.
107. Muñoz A, Kirby AJ, He YD, et al. Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:496-505.
108. Gange SJ, Muñoz A, Schrager LK, et al. Design of nested studies to identify factors related to late progression of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15(Suppl 1):S5-9.